Bumetanide

Product manufactured by Avpak

Application Nr Approved Date Route Status External Links
ANDA209724 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Bumetanide Tablets Are Indicated For The Treatment Of Edema Associated With Congestive Heart Failure, Hepatic And Renal Disease, Including The Nephrotic Syndrome. Almost Equal Diuretic Response Occurs After Oral And Parenteral Administration Of Bumetanide. Therefore, If Impaired Gastrointestinal Absorption Is Suspected Or Oral Administration Is Not Practical, Bumetanide Should Be Given By The Intramuscular Or Intravenous Route. Successful Treatment With Bumetanide Tablets Following Instances Of Allergic Reactions To Furosemide Suggests A Lack Of Cross-Sensitivity.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Bumetanide BUMETANIDE ZINC3813061

Comments